We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 10, 2022

Benefit of Platinum-Based Neoadjuvant Chemotherapy for Nonluminal Subtype Muscle-Invasive Bladder Cancer

The Journal of Urology


Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Urology
Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
J Urol 2022 Mar 01;207(3)541-550, Y Lotan, JJ de Jong, VYT Liu, TA Bismar, SA Boorjian, HC Huang, E Davicioni, OY Mian, JL Wright, A Necchi, MA Dall'Era, HZ Kaimakliotis, PC Black, EA Gibb, JL Boormans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading